歡迎您，來到青旗（上海）生物技術(shù)發(fā)展有限公司！
歡迎您，來到青旗（上海）生物技術(shù)發(fā)展有限公司！
您的位置：網(wǎng)站首頁 > 產(chǎn)品展示 > 細(xì)胞庫 > 細(xì)胞系 > 人彌漫大B淋巴瘤細(xì)胞OCI-Ly3
簡要描述：青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區(qū)，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺，在標(biāo)準(zhǔn)化細(xì)胞庫建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負(fù)責(zé)的態(tài)度，以對科研的高度嚴(yán)謹(jǐn)，以嚴(yán)格的質(zhì)量控制，為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)！
更新時間：2021-05-25
廠商性質(zhì)：生產(chǎn)廠家
瀏覽次數(shù)：346
| 品牌 | 其他品牌 | 貨號 | BFN607200615 |
|---|---|---|---|
| 規(guī)格 | T25培養(yǎng)瓶x1 1.5ml凍存管x2 | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | 僅供科研 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,生物產(chǎn)業(yè) |
細(xì)胞名稱 | 人彌漫大B淋巴瘤細(xì)胞OCI-Ly3 |
| |
貨物編碼 | BFN607200615 | ||
產(chǎn)品規(guī)格 | T25培養(yǎng)瓶x1 | 1.5ml凍存管x2 | |
細(xì)胞數(shù)量 | 1x10^6 | 1x10^6 | |
保存溫度 | 27℃ | -198℃ | |
運(yùn)輸方式 | 常溫保溫運(yùn)輸 | 干冰運(yùn)輸 | |
安全等級 | 1 | ||
用途限制 | 僅供科研用途 2類 | ||
培養(yǎng)體系 | DMEM高糖培養(yǎng)基+20%FBS+1%三抗 | ||
培養(yǎng)溫度 | 37℃ | 二氧化碳濃度 | 5% |
簡介 | 人彌漫大B淋巴瘤細(xì)胞OCI-Ly3細(xì)胞于1983年從52歲男性B細(xì)胞非霍奇金淋巴瘤骨髓樣本中建立。為常規(guī)的藥物篩選模型，懸浮培養(yǎng)，易聚團(tuán)。引種自DSMZ（ACC-761） | ||
注釋 | Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: LL-100 blood cancer cell line panel. Part of: MD Anderson Cell Lines Project. From: Ontario Cancer Institute (OCI); Toronto; Canada. Doubling time: ~24 hours (DSMZ). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: Genome sequenced. Omics: H3K9ac ChIP-seq epigenome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis. Caution: A cell line, now termed GNE-587170 (CVCL_AT69), was mistakenly distributed by OCI to a number of groups under the designation OCI-Ly-3, the origin of that cell line is now known. Derived from sampling site: Bone marrow. | ||
STR信息 | Amelogenin X,Y CSF1PO 10,12 D5S818 12 D7S820 11,12 D13S317 11 D16S539 11,12 TH01 7,9.3 TPOX 8,12 vWA 17 | ||
參考文獻(xiàn) | PubMed=3567358 Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J.R., Lockwood G., Minden M.D., Messner H.A. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 69:1307-1314(1987)
PubMed=8574164; DOI=10.3109/10428199509059672 Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A. p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leuk. Lymphoma 19:165-171(1995)
PubMed=10676951; DOI=10.1038/35000501 Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson J. Jr., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511(2000)
PubMed=11807979; DOI=10.1002/gcc.10025 Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Genes Chromosomes Cancer 33:225-234(2002)
PubMed=19278952; DOI=10.1182ood-2009-01-202028 Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., Robetorye R.S., Aguiar R.C.T. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 113:6681-6690(2009)
PubMed=22460905; DOI=10.1038/nature11003 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012)
PubMed=23292937; DOI=10.1073/pnas.1205299110 Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C., Naresh K., Evens A., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013)
PubMed=23699601; DOI=10.1182ood-2013-02-483727 Morin R.D., Mungall K., Pleasance E.D., Mungall A.J., Goya R., Huff R.D., Scott D.W., Ding J., Roth A., Chiu R., Corbett R.D., Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G., Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B., Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S., Jones S., Steidl C., Holt R., Birol I., Moore R., Connors J.M., Gascoyne R.D., Marra M.A. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 122:1256-1265(2013)
PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015)
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017)
PubMed=30285677; DOI=10.1186/s12885-018-4840-5 Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P. Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines. BMC Cancer 18:940-940(2018)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)
PubMed=31160637; DOI=10.1038/s41598-019-44491-x Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G. The LL-100 panel: 100 cell lines for blood cancer studies. Sci. Rep. 9:8218-8218(2019) | ||
驗收細(xì)胞注意事項
1、收到人彌漫大B淋巴瘤細(xì)胞OCI-Ly3細(xì)胞，請查看瓶子是否有破裂，培養(yǎng)基是否漏出，是否渾濁，如有請盡快聯(lián)系。
2、收到人彌漫大B淋巴瘤細(xì)胞OCI-Ly3細(xì)胞 ，如包裝完好，請在顯微鏡下觀察細(xì)胞。,由于運(yùn)輸過程中的問題，細(xì)胞培養(yǎng)瓶中的貼壁細(xì)胞有可能從瓶壁中脫落下來，顯微鏡下觀察會出現(xiàn)細(xì)胞懸浮的情況，出現(xiàn)此狀態(tài)時，請不要打開細(xì)胞培養(yǎng)瓶，應(yīng)立即將培養(yǎng)瓶置于細(xì)胞培養(yǎng)箱里靜止 3-5 小時左右，讓細(xì)胞先穩(wěn)定下，再于顯微鏡下觀察，此時多數(shù)細(xì)胞會重新貼附于瓶壁。如細(xì)胞仍不能貼壁，請用臺盼藍(lán)染色法鑒定細(xì)胞活力，如臺盼藍(lán)染色證實細(xì)胞活力正常請按懸浮細(xì)胞的方法處理。
3、收到人彌漫大B淋巴瘤細(xì)胞OCI-Ly3細(xì)胞后，請鏡下觀察細(xì)胞，用恰當(dāng)方式處理細(xì)胞。若懸浮的細(xì)胞較多，請離心收集細(xì)胞，接種到一個新的培養(yǎng)瓶中。棄掉原液，使用新鮮配制的培養(yǎng)基，使用進(jìn)口胎牛血清。剛接到細(xì)胞，若細(xì)胞不多時 血清濃度可以加到 15％去培養(yǎng)。若細(xì)胞迏到 80%左右 ，血清濃度還是在 10％。
4、收到人彌漫大B淋巴瘤細(xì)胞OCI-Ly3細(xì)胞時如無異常情況 ，請在顯微鏡下觀察細(xì)胞密度，如為貼壁細(xì)胞，未超過80%匯合度時，將培養(yǎng)瓶中培養(yǎng)基吸出，留下 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng)：超過 80%匯合度時，請按細(xì)胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細(xì)胞，吸出培養(yǎng)液，1000 轉(zhuǎn)/分鐘離心 3 分鐘，吸出上清，管底細(xì)胞用新鮮培養(yǎng)基懸浮細(xì)胞后移回培養(yǎng)瓶。
5、將培養(yǎng)瓶置于 37℃培養(yǎng)箱中培養(yǎng)，蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里，存放于 4℃冰箱，以備不時之需。
6、24 小時后，細(xì)胞形態(tài)已恢復(fù)并貼滿瓶壁，即可傳代。（貼壁細(xì)胞）將培養(yǎng)瓶里的培養(yǎng)基倒去，加 3-5ml（以能覆蓋細(xì)胞生長面為準(zhǔn)）PBS 或 Hanks’液洗滌后棄去。加 0.5-1ml 0.25%含 EDTA 的胰酶消化，消化時間以具體細(xì)胞為準(zhǔn)，一般 1-3 分鐘，不超過 5 分鐘。可以放入37℃培養(yǎng)箱消化。輕輕晃動瓶壁，見細(xì)胞脫落下來，加入 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細(xì)胞，使之*脫落，然后將溶液吸入離心管內(nèi)離心，1000rpm/5min。棄上清，視細(xì)胞數(shù)量決定分瓶數(shù)，一般一傳二，如細(xì)胞量多可一傳三，有些細(xì)胞不易傳得過稀，有些生長較快的細(xì)胞則可以多傳幾瓶，以具體細(xì)胞和經(jīng)驗為準(zhǔn)。（懸浮細(xì)胞）用移液管輕輕吹打瓶壁，直接將溶液吸入離心管離心即可。
7、貼壁細(xì)胞 ，懸浮細(xì)胞。嚴(yán)格無菌操作。換液時，換新的細(xì)胞培養(yǎng)瓶和換新鮮的培養(yǎng)液，37℃，5%CO2 培養(yǎng)。
特別提醒： 原瓶中培養(yǎng)基不宜繼續(xù)使用，請更換新鮮培養(yǎng)基培養(yǎng)。
地址：上海市浦東新區(qū)宏祥北路83號
郵箱：cellsupport@bluefcell.com
傳真：
咨詢電話